NCT06401213 - A First-in-Human Safety Trial of MTX-463 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2024

Primary Completion Date

November 15, 2024

Study Completion Date

November 15, 2024

Conditions

Healthy

Interventions

BIOLOGICAL

MTX-463

MTX-463 is an immunoglobin G1 (IgG1) monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1). WISP1 (aka CCN-4) is a matricellular protein that appears to be upregulated locally in response to certain chronic diseases and malignancies.

OTHER

Placebo

Matching Placebo-- Normal Saline

Trial Locations (1)

84124

ICON, Salt Lake City